CORRECTION: Lipocine Q4 EPS $(0.03), Inline
Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 121.43 percent decrease over earnings of $0.14 per share from the same period last year.
12 Health Care Stocks Moving In Friday’s Pre-Market Session
Gainers Immuron (NASDAQ:IMRN) stock increased by 42.2% to $2.29 during Friday’s pre-market session. The company’s market cap stands…
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Reshape Lifesciences (NASDAQ:RSLS) shares increased by 12.7% to $0.34 during Monday's after-market session. The market value of their outstanding shares is at $1.2 million.
Lipocine To Focus On Central Nervous System Conditions; Explores Partnerships For Non-Core Assets
Lipocine Inc (NASDAQ:LPCN) announced its plans to focus on treating Central Nervous System (CNS) disorders. The company’s priority is to advance…
Lipocine Announces Realignment And Forward Focus On Treating CNS Disorders; Announces Planned Monetization Of Non-Core Assets Through Partnerships
Company to apply its proprietary Lip'ral oral drug delivery technology to advance a pipeline of differentiated products for Central Nervous System (CNS) disorders
Initial focus on oral delivery of neuroactive
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Reshape Lifesciences (NASDAQ:RSLS) stock increased by 10.1% to $0.39 during Monday's after-market session. The company's market cap stands at $1.3 million.